Healthcare Market Research Reports

Healthcare, the world's largest industry, is transforming faster than ever. The focus on outcomes based medicine and optimal health management of populations will result in major seismic shifts. Modernization and reform measures are being employed globally by public and private sector organizations to meet the growing need for healthcare. New technologies are being created, offering enormous promise to improve care delivery.

Our Transformational Health practice serves all key industry stakeholders through partnership models that provide access to high-quality content and our global team of industry experts. The practice includes Visionary Health, Life Sciences, Advanced Medical Technologies and Connected Health, focusing on evolving healthcare technologies and covering the entire industry spectrum

  1. 19 Dec 2022  |  North America  |  Market Outlook

    Top 10 for 2023: Growth Opportunities for the Life Sciences Industry

    An increasing focus on biologics, genomics, and multi-omics; the adoption of digital technologies; and a shift to patient-centric models are transforming the life sciences industry. At the same time, the emergence of value-based models, R&D activities to treat complex diseases, and healthcare consumerism provide an impetus to precision medicine. Wi...

    $2,450.00
  2. 16 Nov 2022  |  North America  |  Frost Radar

    Frost Radar™: Cell and Gene Therapy Contract Development and Manufacturing Organizations, 2022

    A Benchmarking System to Spark Companies to Action-Innovation that Fuels New Deal Flow and Growth Pipelines

    As cell and gene therapy (CGT) moves from ultra-rare indications to more common indications, manufacturing capabilities will have to expand to support the commercial requirements of these diseases. Contract research organizations (CROs) can play a critical role in long-term genetic analysis and monitor safety and efficacy up to 15 years after treat...

    $4,950.00
  3. 23 Aug 2022  |  North America  |  Frost Radar

    Frost Radar™: US Liquid Biopsy, 2022

    A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

    The oncology space is maturing rapidly. With the arrival of blood-based assays for cancer screening and the emphasis on early detection, the liquid biopsy segment is seeing increased consolidation and high-impact acquisitions, such as Illumina and GRAIL, Exact Sciences and Thrive Earlier Detection, and Roche Foundation Medicine and Lexent Bio. Comp...

    $4,950.00
  4. 14 Mar 2022  |  North America  |  Market Outlook

    Next-generation Diagnostics Outlook, 2022

    Recovery in Routine Testing and Focus on Personalized Diagnostics to Propel Growth

    In vitro diagnostics introduces new technologies, sequencing methods, novel software algorithms, and multi-omics approaches to realise the goal of personalized medicine. Next-generation diagnostics has been the backbone of COVID-19-related emergency diagnosis, with an estimated 25% to 30% of revenue during 2020 and early 2021 related to this testin...

    $4,950.00
  5. 08 Mar 2022  |  North America  |  Market Outlook

    Global Pharmaceuticals Outlook, 2022

    The Digitalization of the Pharmaceuticals Value Chain is Opening up New Growth Opportunities for Stakeholders

    Frost & Sullivan offers an outlook for the global pharmaceuticals market for 2022-2026, including emerging trends and growth opportunities. Prioritizing booster doses over initial dose coverage is negatively impacting the global mitigation of the COVID-19 pandemic, which is resulting in severe implications on health and social and economic well-bei...

    $4,950.00
  6. 12 Aug 2021  |  North America  |  Frost Radar

    Frost Radar™: Non-Invasive Prenatal Testing, Global, 2021

    A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

    Non-invasive prenatal testing (NIPT) provides an alternative to invasive, higher-risk tests such as amniocentesis, requiring a maternal blood sample to obtain cell-free DNA from both mother and fetus for analysis. Since NIPTs debut in 2011, laboratories and testing companies have made incremental upgrades to their non-invasive screens, improving ac...

    $4,950.00
  7. 23 Jun 2021  |  Global  |  Frost Radar

    Frost Radar™: Artificial Intelligence-enabled Drug Discovery in the Global Pharmaceutical Industry, 2021

    A Benchmarking System to Spark Companies to Action—Innovation that Fuels New Deal Flow and Growth Pipelines

    Pharmaceutical drug discovery and development suffers from declining success rates with new molecules, and the rate of return has shrunk from 16% in 2011 to almost 11% in 2018. Frost & Sullivan finds that traditional solutions focused primarily on data from limited sources and rule-based computational techniques used to address the understanding of...

    $4,950.00
  8. 26 Mar 2021  |  North America  |  Customer Research

    Global Laboratory Product Purchasing Trends, 2020–2021

    An End-user Perspective on Laboratory Spending Reveals Modest 2021 Budget Increases Following Healthier 2020 Spending

    Readers of one of Frost & Sullivan’s media partners were invited to participate in an online survey in September 2020 that centered on the state of their laboratories in 2020 and their expectations for 2021. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. Where applicable, the study presents yea...

    $4,950.00